Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Specialist in Reno, NV
NPI: 1407891534Primary Practice Location
Center of Hope
5465 Reno Corporate Dr, Reno, NV
Primary Employer
Center of Hope
centerofhopeinc.org
HQ Phone
Get M.D. Peter's Phone Numberphone_androidMobile
Get M.D. Peter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
1991 - 2027
NV State Medical License
1998 - 2027
FL State Medical License
2018 - 2020
MN State Medical License
1994 - 1998
NV State Medical License
American Board of Obstetrics and Gynecology
Obstetrics & Gynecology
American Board of Obstetrics and Gynecology
Gynecologic Oncology
Drexel University College Of Medicine
drexel.edu
Medical School
Until 1990
Mayo Clinic Alix School of Medicine - Rochester
college.mayo.edu
Fellowship • Gynecologic Oncology
1994 - 1997
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Obstetrics and Gynecology
1990 - 1994
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Authors: Mike Janicek, Jeffrey Hines, Alan Gordon, Datchen Tai, Michael Teneriello
Journal: Gynecol Oncol
Publication Date: 2011-10-05
Absence of mutations in DNA mismatch repair genes in sporadic endometrial tumors with microsatellite instability.
Authors: William Cliby
Publication Date: 1996-11
Lead Sponsor: Genelux Corporation
Collaborators: GOG Foundation
Intervention / Treatment: BIOLOGICAL: olvimulogene nanivacirepvec, DRUG: Platinum chemotherapy: carboplatin (preferred) or cisplatin, DRUG: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin, DRUG: Bevacizumab (or biosimilar)
Lead Sponsor: ImmunoGen, Inc.
Intervention / Treatment: DRUG: Mirvetuximab Soravtansine
Lead Sponsor: Gynecologic Oncology Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Questionnaire Administration, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, OTHER: Placebo Administration, DRUG: Metformin Hydrochloride
